Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya

by Owino F, Mandala J, Ambia J, Agot K, Van Damme L
Published 2013-11-01

“We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study

by Shapley-Quinn MK, Manenzhe KN, Agot K, Minnis AM, van der Straten A
Published 2019-02-01

Engaging study participants in interpreting results: lessons from the TRIO study in Kenya and South Africa

by Agot K, Minnis AM, Manenzhe K, Browne EN, Ahmed K, Okello T, van der Straten A
Published 2019-07-01

Implementing good participatory practice guidelines in the FEM-PrEP Preexposure Prophylaxis Trial for HIV Prevention among African Women: a focus on local stakeholder involvement

by Mack N, Kirkendale S, Omullo P, Odhiambo J, Ratlhagana M, Masaki M, Siguntu P, Agot K, Ahmed K, Kapiga S, Lombaard J, Van Damme L, Corneli A
Published 2013-10-01

Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial

by Parker C, Corneli A, Agot K, Odhiambo J, Asewe J, Ahmed K, Skhosana J, Ratlhagana M, Lanham M, Wong C, Deese J, Manongi R, Van Damme L
Published 2014-12-01